Nilotinib: evaluation and analysis of its role in chronic myeloid leukemia (Q39779762)

14 September 2017

Nilotinib: evaluation and analysis of its role in chronic myeloid leukemia (English)

1 reference

14 September 2017

chronic myeloid leukemia

0 references

author name string

Paula Garland

series ordinal

1

1 reference

PubMed ID

21345139

14 September 2017

Jane Apperley

series ordinal

2

1 reference

PubMed ID

21345139

14 September 2017

language of work or name

English

0 references

publication date

1 February 2011

1 reference

14 September 2017

1 reference

14 September 2017

7

1 reference

14 September 2017

2

1 reference

14 September 2017

201-218

1 reference

Clinical algorithms for the treatment of patients with chronic myeloid leukemia: the 2010 perspective

14 September 2017

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.174

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.174

How I treat chronic myeloid leukemia in the imatinib era.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.174

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.174

Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.174

Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.174

Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.174

Response definitions and European Leukemianet Management recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.174

Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.174

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.174

Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.174

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.174

Mechanisms of Resistance to Imatinib and Second-Generation Tyrosine Inhibitors in Chronic Myeloid Leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.174

Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.174

Part II: management of resistance to imatinib in chronic myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.174

Bone marrow mesenchymal stromal cells non-selectively protect chronic myeloid leukemia cells from imatinib-induced apoptosis via the CXCR4/CXCL12 axis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.174

Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.174

Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.174

Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.174

Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.174

Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.174

A comprehensive target selectivity survey of the BCR-ABL kinase inhibitor INNO-406 by kinase profiling and chemical proteomics in chronic myeloid leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.174

Bosutinib: a review of preclinical studies in chronic myelogenous leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.174

Synergistic activity of the Src/Abl inhibitor bosutinib in combination with imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.174

KIT polymorphisms and mutations determine responses of neoplastic mast cells to bafetinib (INNO-406).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.174

AMN107, a novel aminopyrimidine inhibitor of p190 Bcr-Abl activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.174

Low-level expression of proapoptotic Bcl-2-interacting mediator in leukemic cells in patients with chronic myeloid leukemia: role of BCR/ABL, characterization of underlying signaling pathways, and reexpression by novel pharmacologic compounds.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.174

AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.174

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.174

Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.174

Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.174

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.174

Clinical pharmacokinetics of the BCR-ABL tyrosine kinase inhibitor nilotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.174

Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.174

Nilotinib concentration in cell lines and primary CD34(+) chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.174

Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.174

Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.174

Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.174

Clinical pharmacokinetics of tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.174

Effect of grapefruit juice on the pharmacokinetics of nilotinib in healthy participants

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.174

Effects of rifampin and ketoconazole on the pharmacokinetics of nilotinib in healthy participants.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.174

Effect of the proton pump inhibitor esomeprazole on the oral absorption and pharmacokinetics of nilotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.174

Nilotinib for imatinib-resistant or -intolerant chronic myeloid leukemia in chronic phase, accelerated phase, or blast crisis: a single- and multiple-dose, open-label pharmacokinetic study in Chinese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.174

A Phase I/II study of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALL.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.174

Nilotinib treatment in mouse models of P190 Bcr/Abl lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.174

Epidemiologic study on survival of chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia patients with BCR-ABL T315I mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.174

Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.174

Efficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in patients with chronic myeloid leukemia in chronic phase who have failed 2 prior lines of TKI therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.174

Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.174

IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.174

Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.174

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.174

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.174

Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.174

Combination of two but not three current targeted drugs can improve therapy of chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.174

Nilotinib-mediated inhibition of ABCB1 increases intracellular concentration of dasatinib in CML cells: implications for combination TKI therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.174

Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.174

Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.174

Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.174

Danusertib (formerly PHA-739358)--a novel combined pan-Aurora kinases and third generation Bcr-Abl tyrosine kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.174

PHA-680626 exhibits anti-proliferative and pro-apoptotic activity on Imatinib-resistant chronic myeloid leukemia cell lines and primary CD34+ cells by inhibition of both Bcr-Abl tyrosine kinase and Aurora kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.174

AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.174

The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRbeta and FIP1L1-PDGFRalpha in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.174

Activity of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, against human FIP1L1-PDGFR-alpha-expressing cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.174

Effects of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, on human mast cells bearing wild-type or mutated codon 816 c-kit

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.174

Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.174

A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.174

A critical appraisal of conventional and investigational drug therapy in patients with hypereosinophilic syndrome and clonal eosinophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.174

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.174

Pancreatic enzyme elevation in chronic myeloid leukemia patients treated with nilotinib after imatinib failure

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.174

Impaired fasting glucose level as metabolic side effect of nilotinib in non-diabetic chronic myeloid leukemia patients resistant to imatinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.174

Effects of hepatic impairment on the pharmacokinetics of nilotinib: an open-label, single-dose, parallel-group study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.174

Tyrosine kinase inhibitors: the first decade

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.174

Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.174

Chronic myeloid leukemia--therapy in the 20th and 21st centuries

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.174

Hematopoietic stem cells and progenitors of chronic myeloid leukemia express leukemia-associated antigens: implications for the graft-versus-leukemia effect and peptide vaccine-based immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.174

Ex vivo characterization of polyclonal memory CD8+ T-cell responses to PRAME-specific peptides in patients with acute lymphoblastic leukemia and acute and chronic myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.174

Development of a Wilms' tumor antigen-specific T-cell receptor for clinical trials: engineered patient's T cells can eliminate autologous leukemia blasts in NOD/SCID mice

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.174

Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.174

UGT1A1 promoter polymorphism increases risk of nilotinib-induced hyperbilirubinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.174

Translocation of c-abl oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.174

21 January 2018

Identifiers

DOI

10.2217/FON.10.174

1 reference

14 September 2017

1 reference

PubMed ID

21345139